CHAPTER 3 The clinical value of drugs under development in hematological malignancies Adapted from: Two decades of targeted therapies in acute myeloid leukemia Polak TB, Cucchi DGJ, Ossenkoppele GJ, Uyl-De Groot CA, Cloos J, Zweegman S, Janssen JJWM. Leukemia. 2021 Mar;35(3):651-660. The predictive value of a positive phase II ASH abstract for peer-reviewed publication and progression to phase III Cucchi DGJ, Polak TB, Ossenkoppele GJ, Rowe JM, Estey EH. Blood. 2022 Mar 24;139(12):1920-1923.
RkJQdWJsaXNoZXIy MTk4NDMw